Market Cap | 9.82M | P/E | - | EPS this Y | 43.20% | Ern Qtrly Grth | - |
Income | - | Forward P/E | -2.34 | EPS next Y | 14.30% | 50D Avg Chg | -30.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -53.00% |
Dividend | N/A | Price/Book | 0.73 | EPS next 5Y | - | 52W High Chg | -87.00% |
Recommedations | 2.00 | Quick Ratio | - | Shares Outstanding | 11.63M | 52W Low Chg | 19.00% |
Insider Own | 32.98% | ROA | - | Shares Float | - | Beta | - |
Inst Own | 16.96% | ROE | - | Shares Shorted/Prior | 312.56K/364.78K | Price | 0.84 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 106,279 | Target Price | 12.58 |
Oper. Margin | - | Earnings Date | Nov 14 | Volume | 163,868 | Change | 1.07% |
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.
HC Wainwright & Co. | Buy | Dec 22, 21 |
HC Wainwright & Co. | Buy | Dec 22, 21 |